Mycotoxin Testing in Boston & Wellesley, MA

Mycotoxins are toxic secondary metabolites produced by certain species of mold, including Aspergillus, Stachybotrys, Penicillium, and Fusarium. They are released into the environment when these molds grow—most commonly in water-damaged buildings, on contaminated food, or in environments with high humidity and poor ventilation. Exposure occurs primarily through inhalation of mold spores and mycotoxin particles in contaminated indoor environments, as well as through ingestion of mycotoxin-contaminated food.

Yes. Mycotoxins can persist in building materials, dust, and HVAC systems long after visible mold has been remediated, and exposure may have occurred in a previous living or working environment whose effects have continued to accumulate. Additionally, mycotoxin exposure through contaminated food is possible without any environmental mold exposure. Testing is the only reliable way to determine whether mycotoxin burden is present, regardless of the apparent source.

Mycotoxin exposure can contribute to a wide range of symptoms, including chronic fatigue, cognitive fog and memory impairment, headaches, respiratory symptoms, sinus congestion, mood disturbances including anxiety and depression, hormonal disruption, digestive issues, skin changes, joint pain, and recurrent infections. Because these symptoms overlap with many other conditions, mycotoxin exposure is frequently missed as the underlying contributor.

Home mold testing evaluates the presence of mold spores and species in the environment. Mycotoxin testing evaluates the burden of mold-derived toxins that have already accumulated within the patient's body. Both types of assessment can be relevant; identifying the environmental source of exposure and quantifying the body's mycotoxin burden are complementary pieces of information that together provide the most complete picture of mold-related illness.

Mycotoxin reduction protocols typically involve a combination of approaches tailored to the specific mycotoxins identified and each patient's individual clinical picture. Common components include mycotoxin binders—such as activated charcoal, cholestyramine, or bentonite clay—that bind mycotoxins in the gut and support elimination, antifungal support where active fungal colonization is suspected, nutritional repletion, gut health restoration to support elimination pathways, and immune support. Dr. Ahn develops each patient's protocol based on their specific test results and health picture.

The timeline depends on the specific mycotoxins identified, the degree of accumulation, ongoing versus historical exposure, and each patient's individual detoxification capacity. Some patients see meaningful reductions in mycotoxin levels within weeks of beginning a targeted protocol. Those with a more significant burden or ongoing exposure may require a longer course of treatment. Addressing the source of exposure, whether environmental remediation or dietary changes, is an essential component of achieving lasting reduction. Dr. Ahn monitors progress through follow-up testing and adjusts the protocol accordingly.

Yes. Certain mycotoxins, particularly zearalenone, have estrogenic activity and can bind to estrogen receptors, contributing to hormonal disruption in both men and women. Other mycotoxins affect adrenal function, thyroid health, and the broader hormonal axis through their effects on immune function and inflammatory signaling. Dr. Ahn evaluates the hormonal implications of mycotoxin burden as part of every assessment and addresses these connections in the treatment plan.

Ahn Point Wellness is a cash-pay practice and does not accept insurance. Many patients find that HSA and FSA accounts can help offset the cost of testing and treatment. Dr. Ahn will discuss the testing she recommends and associated costs during your consultation.